• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Bausch Health to Announce First-Quarter 2024 Results on May 2

    4/11/24 4:22:00 PM ET
    $BHC
    $NHC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Hospital/Nursing Management
    Health Care
    Get the next $BHC alert in real time by email

    LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.

    Conference Call Details

    Date:

    Thursday, May 2, 2024

    Time:

    8:00 a.m. U.S. EDT

    Webcast:

    http://ir.bauschhealth.com/events-and-presentations

    A replay of the conference call will be available on the investor relations website.

    To participate in the live Q&A session, please register using this link to receive a PIN, which will be sent an hour before the conference call.

    About Bausch Health

    Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health outcomes. We develop, manufacture and market a range of products, primarily in gastroenterology, hepatology, neurology, dermatology, medical aesthetic devices, international pharmaceuticals, and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.

    ###

    Investor Contact: Media Contact:
    Garen Sarafian Kevin Wiggins
    [email protected] [email protected]
    (877) 281-6642 (toll-free) (908) 541-3785

    SOURCE: Bausch Health Companies Inc.



    View the original press release on accesswire.com

    Get the next $BHC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BHC
    $NHC

    CompanyDatePrice TargetRatingAnalyst
    Bausch Health Companies Inc.
    $BHC
    12/9/2025$8.00Equal Weight
    Barclays
    Bausch Health Companies Inc.
    $BHC
    8/2/2024$9.00 → $3.00Neutral → Underweight
    Piper Sandler
    Bausch Health Companies Inc.
    $BHC
    7/10/2024$8.00Mkt Perform
    Raymond James
    Bausch Health Companies Inc.
    $BHC
    9/20/2023$9.00 → $16.00Hold → Buy
    Jefferies
    Bausch Health Companies Inc.
    $BHC
    6/16/2023Outperform → Market Perform
    TD Cowen
    Bausch Health Companies Inc.
    $BHC
    7/29/2022Buy → Hold
    Truist
    Bausch Health Companies Inc.
    $BHC
    7/29/2022$12.00 → $5.00Outperform → Sector Perform
    RBC Capital Mkts
    Bausch Health Companies Inc.
    $BHC
    7/28/2022Overweight → Neutral
    JP Morgan
    More analyst ratings

    $BHC
    $NHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NHC Reports 2025 Year End Earnings

    National HealthCare Corporation (NYSE American: NHC), the nation's oldest publicly traded senior health care company, announced today net operating revenues and grant income for the year ended December 31, 2025 totaled $1,517,781,000 compared to $1,307,382,000 for the year ended December 31, 2024, an increase of 16.1%. The increase in net operating revenues for the 2025 year compared to the 2024 year was due to an 8.4% increase in same-facility net operating revenues, as well as the August 1, 2024 acquisition of White Oak Manor ("White Oak"). The White Oak operations consist of 22 healthcare operations, which includes 15 skilled nursing facilities, two assisted living facilities, four indep

    2/26/26 5:30:00 PM ET
    $NHC
    Hospital/Nursing Management
    Health Care

    Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in Canada

    LAVAL, QC, Feb. 23, 2026 /CNW/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in medical aesthetics, today announced the launch of the Clear + Brilliant® Touch laser in Canada. The device was approved by Health Canada on May 20, 2025, marking an important milestone as demand for non‑invasive skin rejuvenation treatments continues to grow across Canada. With this approval, Canadian physicians are able to offer one of the most advanced dual-wavelength laser technologies on the market, expanding access to customizable treatments that align with the country's growing preference for effective yet approachable s

    2/23/26 8:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health's OraPharma Celebrates 25 Years of ARESTIN® (minocycline HCl) Microspheres

    The only FDA‑approved locally applied antibiotic used with scaling and root planing (SRP) marks a quarter‑century of clinical useLAVAL, QC, Feb. 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its dental products business, OraPharma, today announced the 25th anniversary milestone of ARESTIN® (minocycline HCl) Microspheres, 1 mg, a locally administered antibiotic used as an adjunct to scaling and root planing (SRP) for the reduction of pocket depth in adult patients with periodontitis. ARESTIN is supported by over two decades of clinical experience and remains the only Food and Drug Administration (FDA) approved locally applied antibiotic for this use.Dan Wu, Ph

    2/19/26 8:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    $NHC
    SEC Filings

    View All

    Bausch Health Companies Inc. filed SEC Form 8-K: Leadership Update

    8-K - Bausch Health Companies Inc. (0000885590) (Filer)

    3/2/26 5:17:03 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    National HealthCare Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NATIONAL HEALTHCARE CORP (0001047335) (Filer)

    2/27/26 9:47:21 AM ET
    $NHC
    Hospital/Nursing Management
    Health Care

    SEC Form 10-K filed by National HealthCare Corporation

    10-K - NATIONAL HEALTHCARE CORP (0001047335) (Filer)

    2/26/26 5:16:59 PM ET
    $NHC
    Hospital/Nursing Management
    Health Care

    $BHC
    $NHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sr.VP Patient Srvcs Dodson Vicki L exercised 4,500 units of Shares of Common Stock held in my name at a strike of $90.62 and covered exercise/tax liability with 3,159 units of Shares of Common Stock held in my name, increasing direct ownership by 12% to 12,713 units (SEC Form 4)

    4 - NATIONAL HEALTHCARE CORP (0001047335) (Issuer)

    3/6/26 4:34:54 PM ET
    $NHC
    Hospital/Nursing Management
    Health Care

    Senior VP & CIO Flatt Ben Anderson Sr exercised 12,233 shares at a strike of $80.56 and covered exercise/tax liability with 8,142 shares, increasing direct ownership by 26% to 19,550 units (SEC Form 4)

    4 - NATIONAL HEALTHCARE CORP (0001047335) (Issuer)

    3/6/26 4:27:36 PM ET
    $NHC
    Hospital/Nursing Management
    Health Care

    Senior VP & General Counsel Mccreary Josh A exercised 4,500 shares at a strike of $90.62 and covered exercise/tax liability with 3,202 shares, increasing direct ownership by 11% to 12,698 units (SEC Form 4)

    4 - NATIONAL HEALTHCARE CORP (0001047335) (Issuer)

    3/6/26 4:26:22 PM ET
    $NHC
    Hospital/Nursing Management
    Health Care

    $BHC
    $NHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Bausch Health with a new price target

    Barclays initiated coverage of Bausch Health with a rating of Equal Weight and set a new price target of $8.00

    12/9/25 8:43:03 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Bausch Health from Neutral to Underweight and set a new price target of $3.00 from $9.00 previously

    8/2/24 7:25:50 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on Bausch Health with a new price target

    Raymond James initiated coverage of Bausch Health with a rating of Mkt Perform and set a new price target of $8.00

    7/10/24 8:35:33 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    $NHC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Paulson & Co. Inc. bought $15,625,000 worth of shares (2,500,000 units at $6.25) (SEC Form 4)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    11/28/25 5:38:39 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Paulson John bought $312,490,062 worth of shares (34,721,118 units at $9.00) (SEC Form 4)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    8/14/25 9:35:28 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Paulson John bought $21,267,731 worth of shares (3,243,049 units at $6.56) (SEC Form 4)

    4 - Bausch Health Companies Inc. (0000885590) (Issuer)

    8/13/25 6:51:24 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    $NHC
    Leadership Updates

    Live Leadership Updates

    View All

    NHC Announces W. Andrew Adams Retirement from NHC Board of Directors

    National HealthCare Corporation (NYSE:NHC) announces the retirement of W. Andrew "Andy" Adams from the NHC Board of Directors effective after the annual meeting of shareholders on May 8, 2025. The son of NHC founder, Dr. Carl Adams, Andy Adams has had an unparalleled career of service and leadership at NHC. He originally joined NHC in 1972 as an Executive Officer. Andy then served as NHC's President from 1974 to 2004 and as Chief Executive Officer (CEO) from 1981 to 2004. Andy's service on the NHC Board of Directors began in 1974 where he also served as Chairman from 1994 to 2008. Andy had a significant impact on NHC. During his time in leadership, NHC's revenue grew to over $521 million i

    5/8/25 5:11:00 PM ET
    $NHC
    Hospital/Nursing Management
    Health Care

    Bausch Health Appoints New Chief Medical Officer and Head of R&D

    LAVAL, QC / ACCESSWIRE / December 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce the appointment of Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D. This strategic addition to our leadership team underscores our commitment to innovation, excellence, and enriching lives.Jonathan brings a wealth of experience and a proven track record of success both as a physician-scientist and a leader in the pharmaceutical industry. With over 20 years of expertise in clinical research and drug development, he has consistently demonstrated the ability to drive growth and foster innovation. Most recently, at Bristol-Meyers Squibb,

    12/2/24 8:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bausch Health Welcomes Two New Members to the Executive Leadership Team

    LAVAL, QC / ACCESSWIRE / July 19, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the appointment of two new members to its Executive Leadership Team (ELT).Jean-Jacques Charhon ("JJ") will join the Company as Chief Financial Officer on August 19, 2024. JJ has over 25 years of experience in financial leadership roles with public and private companies across healthcare, high tech and services, primarily at General Electric, Hewlett Packard, Novartis and Purdue Pharma. Upon JJ's arrival, John Barresi, the Company's Interim Chief Financial Officer, will resume his role as SVP, Controller.Aimee Lenar joined the Company on July 15, 2024 as Executive Vice President, US Pharm

    7/19/24 7:00:00 AM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHC
    $NHC
    Financials

    Live finance-specific insights

    View All

    NHC Reports 2025 Year End Earnings

    National HealthCare Corporation (NYSE American: NHC), the nation's oldest publicly traded senior health care company, announced today net operating revenues and grant income for the year ended December 31, 2025 totaled $1,517,781,000 compared to $1,307,382,000 for the year ended December 31, 2024, an increase of 16.1%. The increase in net operating revenues for the 2025 year compared to the 2024 year was due to an 8.4% increase in same-facility net operating revenues, as well as the August 1, 2024 acquisition of White Oak Manor ("White Oak"). The White Oak operations consist of 22 healthcare operations, which includes 15 skilled nursing facilities, two assisted living facilities, four indep

    2/26/26 5:30:00 PM ET
    $NHC
    Hospital/Nursing Management
    Health Care

    BAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTS

    Fourth Quarter Consolidated Revenues of $2.80 billion, up 9% on a Reported basis and up 6% on an Organic (non-GAAP)1 basis over the prior year periodFull-Year Consolidated Revenues of $10.27 billion, up 7% on a Reported basis and 5% on an Organic (non-GAAP)1 basisGAAP Net Loss Attributable to Bausch Health of $112 million for the quarter and GAAP Net Income Attributable to Bausch Health of $157 million for the yearConsolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP)1 of $1.05 billion for the quarter, up 13%, and $3.54 billion for the year, up 7%BAUSCH HEALTH EXCLUDING BAUSCH + LOMB FOURTH QUARTER AND FULL-YEAR 2025 RESULTSDelivered eleventh consecutive quarter of year-over-y

    2/18/26 4:05:00 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NHC Announces Common Dividend

    National HealthCare Corporation (NYSE:NHC), the nation's oldest publicly traded long-term health care company, announced today that it will pay a quarterly dividend of 64 cents per common share to shareholders of record on March 31, 2026 and payable on April 30, 2026. Forward-Looking Statements Statements in this press release that are not historical facts are forward-looking statements. NHC cautions investors that any forward-looking statements made involve risks and uncertainties and are not guarantees of future performance. The risks and uncertainties are detailed from time to time in reports filed by NHC with the S.E.C., including Forms 8-K, 10-Q and 10-K, and include, among others,

    2/13/26 7:00:00 AM ET
    $NHC
    Hospital/Nursing Management
    Health Care

    $BHC
    $NHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by National HealthCare Corporation

    SC 13G - NATIONAL HEALTHCARE CORP (0001047335) (Subject)

    11/8/24 10:24:36 AM ET
    $NHC
    Hospital/Nursing Management
    Health Care

    SEC Form SC 13G filed by Bausch Health Companies Inc.

    SC 13G - Bausch Health Companies Inc. (0000885590) (Subject)

    8/30/24 6:12:52 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Bausch Health Companies Inc.

    SC 13D/A - Bausch Health Companies Inc. (0000885590) (Subject)

    8/19/24 5:48:41 PM ET
    $BHC
    Biotechnology: Pharmaceutical Preparations
    Health Care